Gene · 634
Papers3,222
Newest first. Swiss-Prot's references are curated; PubTator's text mining finds papers that name the gene, not always ones about it.
301 to 320 of 3,222
Download this page as JSON| Title | Journal | Year | PMID | Found by | Source |
|---|---|---|---|---|---|
| Enhanced therapeutic effects of mesenchymal stem cell-derived extracellular vesicles within chitosan hydrogel in the treatment of diabetic foot ulcers. | J Mater Sci Mater Med | 2023 | 37639051 | PubTator, text mining | PubMed |
| Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends. | Signal Transduct Target Ther | 2023 | 37635168 | PubTator, text mining | PubMed |
| An Immune-Related Gene Signature for Predicting Survival and Immunotherapy Efficacy in Esophageal Adenocarcinoma. | Med Sci Monit | 2023 | 37632137 | PubTator, text mining | PubMed |
| Establishment of Replication Deficient Vesicular Stomatitis Virus for Studies of PEDV Spike-Mediated Cell Entry and Its Inhibition. | Microorganisms | 2023 | 37630636 | PubTator, text mining | PubMed |
| Construction and Validation of a Reliable Disulfidptosis-Related LncRNAs Signature of the Subtype, Prognostic, and Immune Landscape in Colon Cancer. | Int J Mol Sci | 2023 | 37629096 | PubTator, text mining | PubMed |
| Oxidative Stress as a Regulatory Checkpoint in the Production of Antiphospholipid Autoantibodies: The Protective Role of NRF2 Pathway. | Biomolecules | 2023 | 37627286 | PubTator, text mining | PubMed |
| The Role and Regulation of the NKG2D/NKG2D Ligand System in Cancer. | Biology (Basel) | 2023 | 37626965 | PubTator, text mining | PubMed |
| Biomarkers for immune checkpoint inhibition in sarcomas - are we close to clinical implementation? | Biomark Res | 2023 | 37612756 | PubTator, text mining | PubMed |
| Immune changes induced by periampullary adenocarcinoma are reversed after tumor resection and modulate the postoperative survival. | Discov Oncol | 2023 | 37610509 | PubTator, text mining | PubMed |
| Novel prognostic gene signature for pancreatic ductal adenocarcinoma based on hypoxia. | World J Surg Oncol | 2023 | 37605192 | PubTator, text mining | PubMed |
| Two waves of evolution in the rodent pregnancy-specific glycoprotein (Psg) gene family lead to structurally diverse PSGs. | BMC Genomics | 2023 | 37605167 | PubTator, text mining | PubMed |
| The tight junction protein claudin 6 is a potential target for patient-individualized treatment in esophageal and gastric adenocarcinoma and is associated with poor prognosis. | J Transl Med | 2023 | 37592303 | PubTator, text mining | PubMed |
| CEACAM1 as a molecular target in oral cancer. | Aging (Albany NY) | 2023 | 37589542 | PubTator, text mining | PubMed |
| Recombinant human TIM-3 ectodomain expressed in bacteria and recovered from inclusion bodies as a stable and active molecule. | Front Bioeng Biotechnol | 2023 | 37588136 | PubTator, text mining | PubMed |
| A novel stratification framework based on anoikis-related genes for predicting the prognosis in patients with osteosarcoma. | Front Immunol | 2023 | 37575253 | PubTator, text mining | PubMed |
| Role of Next Generation Immune Checkpoint Inhibitor (ICI) Therapy in Philadelphia Negative Classic Myeloproliferative Neoplasm (MPN): Review of the Literature. | Int J Mol Sci | 2023 | 37569880 | PubTator, text mining | PubMed |
| Clinical Significance of Nectins in HCC and Other Solid Malignant Tumors: Implications for Prognosis and New Treatment Opportunities-A Systematic Review. | Cancers (Basel) | 2023 | 37568798 | PubTator, text mining | PubMed |
| TIM-3 as a promising target for cancer immunotherapy in a wide range of tumors. | Cancer Immunol Immunother | 2023 | 37567938 | PubTator, text mining | PubMed |
| A new emerging target in cancer immunotherapy: Galectin-9 (LGALS9). | Genes Dis | 2023 | 37554219 | PubTator, text mining | PubMed |
| Regulatory role of exosomes in colorectal cancer progression and potential as biomarkers. | Cancer Biol Med | 2023 | 37553810 | PubTator, text mining | PubMed |
gene-search-2026-11-11-0.2.0
Sources 12
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- EMBL-EBI's patent proteinsNo added restrictions. Attribution expected
- GenBank's patent filesNo restrictions from NCBI. Submitters may hold rights
- HGNCCC0
- NCBI GenePublic domain (US government)
- NIH's project files and grant-paper linksPublic domain
- Open TargetsCC0 1.0
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- EMBL-EBI's patent proteinsEMBL-EBI's patent protein files from the EPO, JPO, KIPO and USPTO. EMBL-EBI: "EMBL-EBI itself places no additional restrictions on the use or redistribution of the data available via its Data Resources and Tools other than those provided by the original data owners" and "EMBL-EBI expects attribution (e.g. in publications, services or products) for the use of any of its Data Resources and Tools." Read on 11 Nov 2026 at https://www.ebi.ac.uk/about/terms-of-use
- GenBank's patent filesGenBank's patent files. NCBI: "NCBI places no restrictions on the use or distribution of the GenBank data. However, some submitters may claim patent, copyright, or other intellectual property rights in all or a portion of the data they have submitted." Read on 11 Nov 2026 at https://www.ncbi.nlm.nih.gov/genbank/about/
- HGNCCC0: https://www.genenames.org/about/license/
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH's project files and grant-paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/genes/v1/634/papers?page=16